Jinling Pharmaceutical Co Ltd (000919) - Total Liabilities
Based on the latest financial reports, Jinling Pharmaceutical Co Ltd (000919) has total liabilities worth CN¥1.18 Billion CNY (≈ $172.22 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore cash flow conversion of Jinling Pharmaceutical Co Ltd to assess how effectively this company generates cash.
Jinling Pharmaceutical Co Ltd - Total Liabilities Trend (1996–2024)
This chart illustrates how Jinling Pharmaceutical Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Check Jinling Pharmaceutical Co Ltd liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Jinling Pharmaceutical Co Ltd Competitors by Total Liabilities
The table below lists competitors of Jinling Pharmaceutical Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Kardemir Karabuk Demir Celik Sanayi ve Ticaret AS Class D
IS:KRDMD
|
Turkey | TL35.63 Billion |
|
Samsung Electro Mechanics Pref
KO:009155
|
Korea | ₩4.80 Trillion |
|
Zhang Xiaoquan Inc.
SHE:301055
|
China | CN¥333.83 Million |
|
Transcat Inc
NASDAQ:TRNS
|
USA | $176.12 Million |
|
Sichuan Goldstone Orient New Material Equipment Co Ltd
SHE:300434
|
China | CN¥484.37 Million |
|
MTY Food Group Inc
TO:MTY
|
Canada | CA$1.67 Billion |
|
Advanced Nano Products Co. Ltd
KQ:121600
|
Korea | ₩203.23 Billion |
|
Arvinas Inc
NASDAQ:ARVN
|
USA | $284.00 Million |
Liability Composition Analysis (1996–2024)
This chart breaks down Jinling Pharmaceutical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market cap of Jinling Pharmaceutical Co Ltd.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.69 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.31 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.20 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Jinling Pharmaceutical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Jinling Pharmaceutical Co Ltd (1996–2024)
The table below shows the annual total liabilities of Jinling Pharmaceutical Co Ltd from 1996 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥1.24 Billion ≈ $181.49 Million |
+43.29% |
| 2023-12-31 | CN¥865.58 Million ≈ $126.66 Million |
-5.54% |
| 2022-12-31 | CN¥916.30 Million ≈ $134.08 Million |
+0.35% |
| 2021-12-31 | CN¥913.10 Million ≈ $133.61 Million |
+7.37% |
| 2020-12-31 | CN¥850.43 Million ≈ $124.44 Million |
+15.92% |
| 2019-12-31 | CN¥733.62 Million ≈ $107.35 Million |
+14.83% |
| 2018-12-31 | CN¥638.90 Million ≈ $93.49 Million |
-20.45% |
| 2017-12-31 | CN¥803.11 Million ≈ $117.52 Million |
-0.22% |
| 2016-12-31 | CN¥804.90 Million ≈ $117.78 Million |
-13.05% |
| 2015-12-31 | CN¥925.73 Million ≈ $135.46 Million |
+6.25% |
| 2014-12-31 | CN¥871.24 Million ≈ $127.49 Million |
+19.36% |
| 2013-12-31 | CN¥729.94 Million ≈ $106.81 Million |
-0.43% |
| 2012-12-31 | CN¥733.12 Million ≈ $107.28 Million |
+15.81% |
| 2011-12-31 | CN¥633.01 Million ≈ $92.63 Million |
+16.26% |
| 2010-12-31 | CN¥544.47 Million ≈ $79.67 Million |
+35.92% |
| 2009-12-31 | CN¥400.59 Million ≈ $58.62 Million |
+23.54% |
| 2008-12-31 | CN¥324.25 Million ≈ $47.45 Million |
-22.21% |
| 2007-12-31 | CN¥416.86 Million ≈ $61.00 Million |
+26.17% |
| 2006-12-31 | CN¥330.39 Million ≈ $48.35 Million |
+17.82% |
| 2005-12-31 | CN¥280.42 Million ≈ $41.03 Million |
-13.14% |
| 2004-12-31 | CN¥322.83 Million ≈ $47.24 Million |
+26.08% |
| 2003-12-31 | CN¥256.06 Million ≈ $37.47 Million |
-13.72% |
| 2002-12-31 | CN¥296.79 Million ≈ $43.43 Million |
-3.18% |
| 2001-12-31 | CN¥306.54 Million ≈ $44.86 Million |
+89.97% |
| 2000-12-31 | CN¥161.37 Million ≈ $23.61 Million |
+5.30% |
| 1999-12-31 | CN¥153.24 Million ≈ $22.42 Million |
+28.09% |
| 1998-12-31 | CN¥119.63 Million ≈ $17.51 Million |
+49.12% |
| 1997-12-31 | CN¥80.23 Million ≈ $11.74 Million |
+3.85% |
| 1996-12-31 | CN¥77.25 Million ≈ $11.30 Million |
-- |
About Jinling Pharmaceutical Co Ltd
Jinling Pharmaceutical Company Limited manufactures and sells pharmaceutical products in China and internationally. The company offers Mailuoning injection/oral solutions for the treatment of thromboangiitis obliterans, arteriosclerosis obliterans, cerebral thrombosis and sequelae, multiple arteriosclerosis, phlebitis, acute arterial embolism of the limbs, diabetic gangrene, venous thrombosis, an… Read more